Genelux (GNLX) Return on Capital Employed (2023 - 2026)

Genelux (GNLX) posted quarterly Return on Capital Employed of 187.59% for Q1 2026, up 10.86% quarter-over-quarter from 210.45% in Q4 2025.

Genelux (GNLX) Return on Capital Employed (2023 - 2026) Analysis & Trends

Genelux's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 187.59% for Q1 2026.

In Q1 2026, Return on Capital Employed changed N/A year-over-year to 187.59%; the TTM figure through Mar 2026 stood at 187.59% (changed N/A YoY), while the FY2025 annual figure was 160.87%, down 3098.0% from the prior year.
Return on Capital Employed for Q1 2026 stood at 187.59%, up from 210.45% in the prior quarter.
The five-year high for Return on Capital Employed was 77.88% in Q3 2024, with the low at 210.45% in Q4 2025.
The 4-year median for Return on Capital Employed is 121.66% (2024), against an average of 131.85%.
The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 469 bps in 2024, then tumbled 10684 bps in 2025.
Genelux's Return on Capital Employed stood at 98.92% in 2023, then retreated by 5 bps to 103.62% in 2024, then sank by 103 bps to 210.45% in 2025, then rose by 11 bps to 187.59% in 2026.
Business Quant data shows GNLX's Return on Capital Employed at 187.59% in Q1 2026, 210.45% in Q4 2025, and 142.82% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	10.74%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-38.20%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	26.09%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-6.85%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-50.93%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	7.88%
10	Genelux	119.87 Mn	119.87 Mn	-	-187.59%

Download Data